U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C13H17Br2NO2.ClH
Molecular Weight 415.549
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEMBREXINE HYDROCHLORIDE

SMILES

Cl.O[C@H]1CC[C@@H](CC1)NCC2=C(O)C(Br)=CC(Br)=C2

InChI

InChIKey=BGRWLVRJIPTKQW-PFWPSKEQSA-N
InChI=1S/C13H17Br2NO2.ClH/c14-9-5-8(13(18)12(15)6-9)7-16-10-1-3-11(17)4-2-10;/h5-6,10-11,16-18H,1-4,7H2;1H/t10-,11-;

HIDE SMILES / InChI

Molecular Formula C13H17Br2NO2
Molecular Weight 379.088
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/3363832 | http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500013623.pdf

Dembrexine is a mucolytic agent which reduces the viscosity of respiratory mucus. It improves movement of mucus in small airways. Dembrexine increases secretion of the serous cells in the glands of the nasal, tracheal and bronchial cells and in type II alveolar cells. It also possesses an anti-tussive effect. Dembrexine is used in the treatment of respiratory disease in horses. All respiratory infections with increased secretions. Acute, sub-acute bronchitis. Chronic respiratory disease. Infection of the upper airways.

Originator

Curator's Comment: # Boehringer Ingelheim Gmbh

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Sputolosin

Approved Use

The drug is indicated for the treatment of respiratory disease in horses. All respiratory infections with increased secretions. Acute, sub-acute bronchitis. Chronic respiratory disease. Infection of the upper airways.
Palliative
Sputolosin

Approved Use

The drug is indicated for the treatment of respiratory disease in horses. All respiratory infections with increased secretions. Acute, sub-acute bronchitis. Chronic respiratory disease. Infection of the upper airways.
Palliative
Sputolosin

Approved Use

The drug is indicated for the treatment of respiratory disease in horses. All respiratory infections with increased secretions. Acute, sub-acute bronchitis. Chronic respiratory disease. Infection of the upper airways.
Palliative
Sputolosin

Approved Use

The agent is indicated for the treatment of foal pneumonia.
PubMed

PubMed

TitleDatePubMed
The mucolytic effect of Sputolosin in horses with respiratory disease.
1988 Jan 30
Patents

Sample Use Guides

Twice daily administration of 0.3 mg active ingredient per kg bodyweight. Adult horses (500 kg): 30 g powder twice daily in the food. Small horses, ponies and foals: 10 g powder per 170 kg bodyweight twice daily.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 18:49:59 GMT 2023
Edited
by admin
on Fri Dec 15 18:49:59 GMT 2023
Record UNII
J32Z420496
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DEMBREXINE HYDROCHLORIDE
Common Name English
PHENOL, 2,4-DIBROMO-6-(((4-HYDROXYCYCLOHEXYL)AMINO)METHYL)-, HYDROCHLORIDE, TRANS-
Common Name English
TRANS-4-((3,5-DIBROMO-2-HYDROXYBENZYL)AMINO)CYCLOHEXANOL HYDROCHLORIDE
Systematic Name English
Classification Tree Code System Code
WHO-VATC QR05CB90
Created by admin on Fri Dec 15 18:49:59 GMT 2023 , Edited by admin on Fri Dec 15 18:49:59 GMT 2023
Code System Code Type Description
PUBCHEM
19381318
Created by admin on Fri Dec 15 18:49:59 GMT 2023 , Edited by admin on Fri Dec 15 18:49:59 GMT 2023
PRIMARY
EPA CompTox
DTXSID70967151
Created by admin on Fri Dec 15 18:49:59 GMT 2023 , Edited by admin on Fri Dec 15 18:49:59 GMT 2023
PRIMARY
CAS
52702-51-9
Created by admin on Fri Dec 15 18:49:59 GMT 2023 , Edited by admin on Fri Dec 15 18:49:59 GMT 2023
PRIMARY
SMS_ID
300000029158
Created by admin on Fri Dec 15 18:49:59 GMT 2023 , Edited by admin on Fri Dec 15 18:49:59 GMT 2023
PRIMARY
FDA UNII
J32Z420496
Created by admin on Fri Dec 15 18:49:59 GMT 2023 , Edited by admin on Fri Dec 15 18:49:59 GMT 2023
PRIMARY
Related Record Type Details
SOLVATE->ANHYDROUS
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY